Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 30:50:102057.
doi: 10.1016/j.rmcr.2024.102057. eCollection 2024.

Tezepelumab in a case of severe asthma exacerbation and influenza-pneumonia on VV-ECMO

E Grasmuk-Siegl  1   2 , E Xhelili  1   2 , D Doberer  1   2 , M H Urban  1   2 , A Valipour  1   2
Affiliations
Case Reports

Tezepelumab in a case of severe asthma exacerbation and influenza-pneumonia on VV-ECMO

E Grasmuk-Siegl et al. Respir Med Case Rep. .

Abstract

We present a case of 43-year-old male patient with broadly by Omalizumab, Mepolizumab and Benralizumab pretreated allergic asthma, who suffered a near fatal exacerbation, triggered by an influenza A infection. Due to massive bronchoconstriction with consecutive hypercapnic ventilatory failure veno-venous ECMO therapy had to be implemented. Hence, guideline directed asthma therapy a substantial bronchodilatation could not be achieved. After administration of a single dose Tezepelumab, a novel TLSP-inhibitor, and otherwise unchanged therapy we documented a significant reduction in intrinsic PEEP measured via a naso-gastric balloon catheter and a narrowing in the expiratory flow curve of the ventilator within 24 hours. The consecutive ventilatory improvement allowed the successful weaning from veno-venous ECMO therapy and invasive ventilation.

Keywords: Allergic asthma; Biologicals; Extracorporeal membrane oxygenation; Near fatal exacerbation; Respiratory critical care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Trend of intrinsic PEEP during VV-ECMO run.
See this image and copyright information in PMC

References

    1. Abbas F., Georas S., Cai X., Khurana S. Asthma biologics: real-world effectiveness, impact of switching biologics, and predictors of response. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. Dezember. 2021;127(6):655–660.e1. - PubMed
    1. Pérez de Llano L., Cisneros C., Domínguez-Ortega J., Martínez-Moragón E., Olaguibel J.M., Plaza V., u a. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response. J Investig. Allergol. Clin. Immunol. August 2022;0;30 - PubMed
    1. Bourdin A., Charriot J., Boissin C., Ahmed E., Suehs C., De Sevin A., u a. Will the asthma revolution fostered by biologics also benefit adult ICU patients? Allergy. August 2021;76(8):2395–2406. - PubMed
    1. Tan W.C. Viruses in asthma exacerbations. Curr Opin Pulm Med. Januar. 2005;11(1):21–26. - PubMed
    1. Sposato B., Croci L., Canneti E., Di Tomassi M., Migliorini M.G., Ricci A., u a. Influenza A H1N1 and severe asthma exacerbation. Eur Rev Med Pharmacol Sci. Mai. 2010;14(5):487–490. - PubMed

Publication types

LinkOut - more resources